Inovio Pharmaceuticals (NSDQ:INO) announced that Thermo Fisher Scientific (NYSE:TMO) will manufacture its COVID-19 vaccine candidate. Plymouth Meeting, Pa.-based Inovio said in a news release yesterday that Thermo Fisher signed a letter of intent to manufacture the INO-4800 COVID-19 vaccine candidate, joining a consortium of third-party manufacturers that aim to produce 100 million doses of Inovio’s vaccine by […]
Inovio Pharmaceuticals
Inovio to scale up production of smart delivery device for potential COVID-19 vaccine
Inovio Pharmaceuticals (NSDQ:INO) announced that it received $71 million from the U.S. Defense Dept. to support its Cellectra 3PSP smart device. Funding from the DoD is set to support large-scale manufacturing for the Cellectra 3PSP and the procurement of Cellectra 2000 devices, which are used to deliver Inovio’s INO-4800 COVID-19 vaccine candidate directly into the skin. […]
OncoSec, Inovio testing COVID-19 vaccines
OncoSec Medical (NSDQ:ONCS) and Inovio Pharmaceuticals (NSDQ:INO) announced that they are testing potential COVID-19 vaccines after the latter received investigational new drug clearance from the FDA. Inovio received an IND nod, while OncoSec’s is pending, but both companies are pursuing a first-in-human Phase 1 clinical trial for their vaccines, according to separate news releases. OncoSec is using […]
Inovio lands $8m Defense grant for intradermal delivery device
Inovio Pharmaceuticals (NSDQ:INO) said last week that it won an $8 million grant from a U.S. Defense Dept. agency for the intradermal delivery device it’s developing. The U.S. Defense Threat Reduction Agency agreed to put more than $8.1 million toward the development of Plymouth Meeting, Pa.-based Inovio’s Cellectra 3PSP, a portable, battery-powered intradermal device to deliver […]
Inovio prices $65m senior notes offering
Inovio Pharmaceuticals (NSDQ:INO) said today that it priced an offering of $65 million of 6.5% convertible senior notes due 2024. The Plymouth Meeting, Penn.-based company also gave initial purchasers a 13-day option to buy up to an additional $20 million in notes. Inovio expects to reel in roughly $62.7 million in net proceeds from the offering […]
Inovio touts intradermal delivery of HIV vaccine
Inovio Pharmaceuticals (NSDQ:INO) reported today that its synthetic HIV vaccine, Pennvax-GP, demonstrated durable antibody and T cell immune responses throughout a Phase I trial. The company found that Pennvax-GP plasmids delivered intradermally with Inovio’s Cellectra device triggered equivalent or superior immune responses in healthy volunteers compared to intramuscular delivery of the plasmids using the same device. […]
Inovio launches Ph1 study of Hep C vaccine
Inovio Pharmaceuticals (NSDQ:INO) and its partner, GeneOne Life Science (KSE:011000), said today that the companies have dosed the first patient in a Phase I study designed to test a preventive vaccine against hepatitis C infection. The companies plan to recruit 24 study participants to evaluate Inovio’s GLS-6150 candidate. Participants will include people who have a sustained […]
Inovio Pharma shares fall on Q1 miss
Shares in Inovio Pharmaceuticals (NSDQ:INO) have fallen today after the biotech company missed expectations on Wall Street with its first quarter earnings results. The Plymouth Meeting, Penn.-based company posted losses of $32.4 million, or 36¢ per share, on sales of $1.5 million for the three months ended March 31, seeing losses grow 40.1% while sales shrunk […]
Inovio snags $56m award for Lassa fever, MERS vaccines
Inovio Pharmaceuticals (NSDQ:INO) inked a $56 million partnership with the Coalition for Epidemic Preparedness Innovations to develop vaccine candidates against Lassa fever and middle east respiratory syndrome. According to the terms of the deal, CEPI is slated to support Inovio’s preclinical and clinical efforts through to Phase II trials of INO-4500, its Lassa fever vaccine, and […]
Inovio Pharmaceuticals logs Q4 earnings, sales beat
Inovio Pharmaceuticals (NSDQ:INO) topped sales and earnings estimates on Wall Street yesterday with its fourth quarter and full year results. The Plymouth Meeting, Pa.-based company posted a net loss of -$21.5 million on sales of $8.8 million for the 3 months ended Dec. 31, for bottom-line growth of 17.9% on sales growth of 3.5% compared with […]
